PET/CT在前列腺癌中的应用综述
本综述通过MEDLINE检索,聚焦18F-NaF、胆碱、fluciclovine及PSMA靶向PET/CT在前列腺癌检测中的应用。NaF PET/CT检测骨转移敏感性高但特异性较低;胆碱PET/CT在生化复发时显著优于常规影像;fluciclovine和PSMA靶向示踪剂在初诊和复发分期中初步显示前景,但需更大样本确认。
要点
- NaF PET/CT检测骨转移敏感性高但特异性较低。
- 胆碱PET/CT在生化复发时显著优于常规影像检测转移灶。
- fluciclovine和PSMA靶向PET/CT在初诊和复发分期中初步显示前景,需更大样本确认。
核心结论
- PET/CT已成为前列腺癌初诊和复发分期的有前景手段,新型示踪剂提高了对小/早期转移灶的检测准确性。
- PET/CT检测到的隐匿病灶的临床意义需系统评估,需明确其自然史及转移导向治疗的反应和影响。
研究设计与样本
- 综述:通过MEDLINE检索关键词「prostate cancer」「PET」「PET/CT」「PET/MR」,限于18F-NaF、胆碱、fluciclovine和PSMA靶向PET/CT。
主要发现
- NaF PET/CT检测骨转移敏感性高但特异性相对较低。
- 胆碱PET/CT研究最广泛,特异性较优但敏感性低,尤其在低PSA水平时。
- 胆碱PET/CT在生化复发时检测转移灶显著优于常规影像。
- fluciclovine和PSMA靶向示踪剂在初诊和复发分期中初步显示前景,但优越性待更大样本确认。
临床怎么用
- PET/CT可用于前列腺癌初诊和复发分期,不同示踪剂性能各异,需结合临床场景选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer. METHODS: We searched MEDLINE using the terms 'prostate cancer', 'PET', 'PET/CT' and 'PET/MR'). The current review was limited to 18F-NaF PET/CT, choline-based PET/CT, fluciclovine PET/CT and PSMA-targeted PET/CT, as these modalities have been the most widely adopted. RESULTS: NaF PET/CT has shown efficacy in detecting bone metastases with high sensitivity, but relatively low specificity. Currently, choline PET/CT has been the most extensively studied modality. Although having superior specificity, choline PET/CT suffers from low sensitivity, especially at low PSA levels. Nevertheless, choline PET/CT was found to significantly improve upon conventional imaging modalities (CIM) in the detection of metastatic lesions at biochemical recurrence (BCR). Newer methods using fluciclovine and PSMA-targeted radiotracers have preliminarily demonstrated great promise in primary and recurrent staging of prostate cancer. However, their superior efficacy awaits confirmation in larger series. CONCLUSIONS: PET/CT has emerged as a promising staging modality for both primary and recurrent prostate cancer. Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. Efforts should be aimed at defining their natural history as well as responsiveness and impact of metastasis-directed therapy.
引用
- Li R, Ravizzini GC, Gorin MA, et al. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 29230009. doi:10.1038/s41391-017-0007-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。